welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics


CureDuchenne, a nonprofit global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), is enthusiastic with today’s announcement that Exonics Therapeutics, a research company focused on CRISPR/Cas-9 technologies to treat Duchenne muscular dystrophy, has been acquired by Vertex. The acquisition by Vertex, a successful and well-respected biotech company, validates CureDuchenne’s venture philanthropy business model of funding early stage science to advance promising Duchenne research projects.

Nonprofit CureDuchenne Is Encouraged To See Gene Editing For Duchenne Advance Through Vertex’s Acquisition Of Exonics Therapeutics